Literature DB >> 10722484

A rapid phenotypic assay for detection of acyclovir-resistant varicella-zoster virus with mutations in the thymidine kinase open reading frame.

R Sahli1, G Andrei, C Estrade, R Snoeck, P R Meylan.   

Abstract

Susceptibility assays by cell culture methods are time-consuming and are particularly difficult to perform with varicella-zoster virus (VZV). To overcome this limitation, we have adapted a functional test of the viral thymidine kinase (TK) in TK-deficient (tdk mutant) bacteria to detect ACV-resistant VZV in clinical samples. After PCR amplification, the complete viral TK open reading frame (ORF) is purified from PCR primers, digested with two restriction enzymes, and ligated in an oriented fashion into a bacterial expression vector. The ligation products are then used to transform tdk mutant bacteria. After transformation, an aliquot of the bacteria is plated onto a plate with minimal medium containing (i) ampicillin to select for plasmids carrying the viral TK ORF and (ii) isopropyl beta-D-thiogalactopyranoside (IPTG) to induce its expression. An identical aliquot of bacteria is also plated onto a medium containing, in addition to the components described above, 5-fluorodeoxyuridine (FUdR). Compared to the number of transformants on FUdR-free medium, the number of colonies carrying TK derived from susceptible strains was reduced by 86%, on average, in the presence of FUdR. In contrast, the number of transformants carrying TK from resistant strains with a mutant TK were reduced by only 4%, on average, on FUdR-containing plates. We have assessed the validity of this assay with cell culture isolates and several clinical samples including two cerebrospinal fluid samples from which no virus could be isolated. This colony reduction assay allowed the correct identification of the TK phenotype of each VZV isolate tested and can be completed within 3 days of receipt of the sample.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722484      PMCID: PMC89785          DOI: 10.1128/AAC.44.4.873-878.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.

Authors:  A Gaudreau; E Hill; H H Balfour; A Erice; G Boivin
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

2.  Characterization of a DNA polymerase mutant of herpes simplex virus from a severely immunocompromised patient receiving acyclovir.

Authors:  P Collins; B A Larder; N M Oliver; S Kemp; I W Smith; G Darby
Journal:  J Gen Virol       Date:  1989-02       Impact factor: 3.891

3.  Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus.

Authors:  E M Swierkosz; D R Scholl; J L Brown; J D Jollick; C A Gleaves
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

4.  Acyclovir-resistant herpes simplex virus infection due to altered DNA polymerase.

Authors:  A C Parker; J I Craig; P Collins; N Oliver; I Smith
Journal:  Lancet       Date:  1987-12-19       Impact factor: 79.321

5.  The complete DNA sequence of varicella-zoster virus.

Authors:  A J Davison; J E Scott
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

6.  Molecular analysis of the pyrimidine deoxyribonucleoside kinase gene of wild-type and acyclovir-resistant strains of varicella-zoster virus.

Authors:  M H Sawyer; G Inchauspe; K K Biron; D J Waters; S E Straus; J M Ostrove
Journal:  J Gen Virol       Date:  1988-10       Impact factor: 3.891

7.  Prolonged cutaneous herpes zoster in acquired immunodeficiency syndrome.

Authors:  W B Hoppenjans; M R Bibler; R L Orme; A M Solinger
Journal:  Arch Dermatol       Date:  1990-08

8.  Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

Authors:  S L Sacks; R J Wanklin; D E Reece; K A Hicks; K L Tyler; D M Coen
Journal:  Ann Intern Med       Date:  1989-12-01       Impact factor: 25.391

9.  Acyclovir-resistant varicella zoster virus infection after chronic oral acyclovir therapy in patients with the acquired immunodeficiency syndrome (AIDS).

Authors:  M A Jacobson; T G Berger; S Fikrig; P Becherer; J W Moohr; S C Stanat; K K Biron
Journal:  Ann Intern Med       Date:  1990-02-01       Impact factor: 25.391

10.  Continuous varicella-zoster infection associated with acyclovir resistance in a child with AIDS.

Authors:  S Pahwa; K Biron; W Lim; P Swenson; M H Kaplan; N Sadick; R Pahwa
Journal:  JAMA       Date:  1988-11-18       Impact factor: 56.272

View more
  3 in total

1.  Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.

Authors:  J Bestman-Smith; I Schmit; B Papadopoulou; G Boivin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  Identification of a varicella-zoster virus replication inhibitor that blocks capsid assembly by interacting with the floor domain of the major capsid protein.

Authors:  Naoki Inoue; Misato Matsushita; Yoshiko Fukui; Souichi Yamada; Mihoko Tsuda; Chizuka Higashi; Keiko Kaneko; Hideki Hasegawa; Toyofumi Yamaguchi
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

3.  Drug resistance of clinical varicella-zoster virus strains confirmed by recombinant thymidine kinase expression and by targeted resistance mutagenesis of a cloned wild-type isolate.

Authors:  Anne-Kathrin Brunnemann; Kathrin Bohn-Wippert; Roland Zell; Andreas Henke; Martin Walther; Oliver Braum; Gregor Maschkowitz; Helmut Fickenscher; Andreas Sauerbrei; Andi Krumbholz
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.